Asep Inc. in Final Stage of Approval Process for NASDAQ Listing Registration Statement
VANCOUVER, BC, Nov. 17, 2023 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce it is in the final stage of its approval process for the draft registration statement on Form F-1 which was filed with the U.S. Securities and Exchange Commission (the “SEC”) for its planned listing and trading of common shares on the NASDAQ stock exchange.
Related news for (SEPSF)
- Asep Medical Featured in National Documentary
- Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
- Asep Medical Confirms the Use of AI – Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
- Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
- ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT